ICAP-Columbia University Mailman School of Public Health, Columbia University, New York, NY, USA.
Pediatr Infect Dis J. 2013 Aug;32(8):e341-7. doi: 10.1097/INF.0b013e31828c2744.
BACKGROUND: Efforts to scale-up HIV treatment in high burden countries have resulted in wider access to care, improved survival and decreased morbidity for HIV-infected children. The country of Rwanda has made significant achievements in expanding coverage of pediatric HIV services. METHODS: We describe the extent of and factors associated with mortality and lost to follow-up (LTF) in children (<15 years) enrolled in HIV care at 39 ICAP-supported facilities across Rwanda from 2004 to 2010 by antiretroviral treatment (ART) status. We estimated the 1-year cumulative incidence of death and LTF among all children enrolled in care (pre-ART) and children on ART. Survival analysis was used to evaluate factors associated with death and LTF in both groups. RESULTS: Between January 2004 and June 2010, 3244 children with a median age of 5.7 years (interquartile range 2.8-9.6) enrolled in HIV care. One-year cumulative incidence for death and LTF among pre-ART children was 4% (95% confidence interval [CI]: 3-5%) and 5% (95% CI: 4-6%), respectively. Overall, 2035 (63%) children initiated ART, median age 6.3 years (interquartile range 3.3-10.4): 1-year Kaplan-Meier estimates of death and LTF were 3% (95% CI: 3-4%) and 1% (95% CI: 1-2%), respectively. Factors associated with an increased hazard for death among pre-ART children included being <18 months old versus ≥5 years (adjusted sub hazard ratio [aSHR] = 4.4, 95% CI: 2.9-6.8) and World Health Organization stage IV versus I (aSHR = 4.1, 95% CI: 2.0-8.4), whereas children entering care through prevention of mother-to-child transmission had lower hazard than those from voluntary counseling and testing (aSHR = 0.50, 95% CI: 0.25-1.0). Markers of advanced disease, including severe immunosuppression (aSHR = 0.25, 95% CI: 0.12-0.54), and enrollment in care in rural versus urban clinics (aSHR = 0.71, 95% CI: 0.53-0.97) were protective against LTF. For children on ART, factors associated with hazard of death included younger age (adjusted hazard ratio [aHR] <18 months versus ≥5 years = 2.1, 95% CI: 1.3-3.6), severe malnutrition versus not malnourished (aHR = 3.2, 95% CI: 1.3-8.1), advanced World Health Organization stage (aHR IV versus I = 9.8, 95% CI: 3.5-27.4) and severe immunodeficiency versus no evidence (aHR = 2.3, 95% CI: 1.7-3.3). No associations were observed with LTF among children on ART. CONCLUSIONS: The results demonstrate very high retention among children enrolled in HIV care in Rwanda. Younger children continue to be particularly vulnerable, underscoring the urgent need for early identification, rapid treatment initiation and long-term retention in care.
背景:在高负担国家扩大艾滋病毒治疗工作的努力,使更多的人获得了护理,提高了艾滋病毒感染儿童的生存率,降低了发病率。卢旺达在扩大儿科艾滋病毒服务方面取得了重大成就。
方法:我们描述了在 2004 年至 2010 年期间,39 个由 ICAP 支持的卢旺达医疗机构中,按抗逆转录病毒治疗(ART)状况,登记接受艾滋病毒护理的儿童(<15 岁)的死亡率和失访(LTF)的程度和相关因素。我们估计了所有接受护理(ART 前)和接受 ART 的儿童的 1 年累积死亡率和 LTF 发生率。生存分析用于评估两组儿童死亡和 LTF 的相关因素。
结果:2004 年 1 月至 2010 年 6 月期间,共有 3244 名中位年龄为 5.7 岁(四分位距 2.8-9.6)的儿童登记接受艾滋病毒护理。ART 前儿童的 1 年累积死亡率和 LTF 发生率分别为 4%(95%可信区间:3-5%)和 5%(95%可信区间:4-6%)。总体而言,2035 名(63%)儿童开始接受 ART,中位年龄为 6.3 岁(四分位距 3.3-10.4):1 年 Kaplan-Meier 估计的死亡率和 LTF 分别为 3%(95%可信区间:3-4%)和 1%(95%可信区间:1-2%)。ART 前儿童死亡风险增加的相关因素包括<18 个月与≥5 岁(调整后的亚危险比[aSHR] = 4.4,95%可信区间:2.9-6.8)和世界卫生组织(WHO)IV 期与 I 期(aSHR = 4.1,95%可信区间:2.0-8.4),而通过母婴传播预防途径进入护理的儿童与自愿咨询和检测途径进入护理的儿童相比,死亡风险较低(aSHR = 0.50,95%可信区间:0.25-1.0)。严重免疫抑制(aSHR = 0.25,95%可信区间:0.12-0.54)和在农村诊所而非城市诊所接受护理(aSHR = 0.71,95%可信区间:0.53-0.97)等疾病晚期标志物与 LTF 呈保护关系。对于接受 ART 的儿童,与死亡风险相关的因素包括年龄较小(调整后的危险比[aHR] <18 个月与≥5 岁= 2.1,95%可信区间:1.3-3.6)、严重营养不良与未营养不良(aHR = 3.2,95%可信区间:1.3-8.1)、晚期世界卫生组织(WHO)分期(aHR IV 与 I = 9.8,95%可信区间:3.5-27.4)和严重免疫缺陷与无证据(aHR = 2.3,95%可信区间:1.7-3.3)。在接受 ART 的儿童中,未观察到与 LTF 相关的任何关联。
结论:研究结果表明,卢旺达登记接受艾滋病毒护理的儿童的保留率非常高。年龄较小的儿童继续面临特别脆弱的风险,这突显了迫切需要早期识别、迅速开始治疗和长期保留在护理中。
Pediatr Infect Dis J. 2016-10
J Acquir Immune Defic Syndr. 2013-3-1
Trop Med Int Health. 2017-4
J Acquir Immune Defic Syndr. 2021-7-1
J Acquir Immune Defic Syndr. 2019-3-1
Bull World Health Organ. 2010-7-1